Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
IONS Ionis Pharmaceuticals
40.970+0.470+1.16%
Close
02/07 16:00 ET
High
41.010
Open
40.470
Turnover
23.74M
Low
39.940
Pre Close
40.500
Volume
584.64K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Holdings Lowered by Bellevue Group AG
Bellevue Group AG decreased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) by 3.2% during the third quarter, according to its most recent disclosure with the Securities & Exchan
SVB Securities Adjusts Ionis Pharmaceuticals Price Target to $34 From $33, Maintains Market Perform Rating
08:10 AM EST, 02/03/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
SVB Securities Sticks to Its Hold Rating for Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals Is Maintained at Market Perform by SVB Leerink
Ionis Pharmaceuticals Price Target Raised to $34.00/Share From $33.00 by SVB Leerink
Ionis Pharmaceuticals Price Target Raised to $34.00/Share From $33.00 by SVB Leerink
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $34
SVB Leerink analyst Joseph Schwartz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $33 to $34.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $177,390.00 in Stock
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Rating) EVP Patrick R. O'neil sold 4,500 shares of the company's stock in a transaction on Monday, January 30th. The stock was sold at an average price
Insider Sell: Ionis Pharmaceuticals
01:52 PM EST, 02/02/2023 (MT Newswires) -- Patrick R. O'Neil, Executive Vice President, Chief Legal Officer and General Counsel, on January 30, 2023, sold 9,000 shares in Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals: GSK Advances Bepirovirsen Into Phase 3 Development
Ionis Granted FDA Fast Track Status for Dyslipidemia Candidate
Company Overview
More
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
CEO： Dr. Brett P. Monia, PhD
Market： NASDAQ
Listing Date： 04/17/1991
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet